URGN Stock Catalyst: UroGen Pharma Ltd. Faces Class Action Lawsuit Over Drug Effectiveness and Study Design

Jun 11, 2025 · 7:47pm ET

Lawsuit alleges false and misleading statements about UGN-102 and ENVISION study.

Max move

+71.2%

High of day $12.50

Sparker timei

7:47pm ET

URGN · Jun 11, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

UroGen Pharma Ltd. (URGN) is facing a class action lawsuit filed by multiple law firms, including Faruqi & Faruqi, LLP, Bronstein, Gewirtz & Grossman, LLC, The Gross Law Firm, Law Offices of Howard G. Smith, and BFA Law, on June 12, 2025. The lawsuit alleges that the company made false and misleading statements regarding the effectiveness of its drug UGN-102 and the design of its clinical study ENVISION.

The lawsuit claims that UroGen Pharma Ltd. overstated the effectiveness of UGN-102 and misrepresented the design and outcomes of the ENVISION study. The complaint includes specific allegations related to stock price fluctuations, with the stock price dropping from $3.37 to $2.54, a decline of 25.8%, and another drop of 44.7% at a later point.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time URGN sparks.

Download Sniper App →

Catch the next URGN-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →